Cart
×
WEBINAR: Edgewise
A Fireside Chat with Mike Kelly and Edgewise Therapeutics: A Duchenne Program Update Wednesday, September 3, 2025 WATCH HERE
Edgewise Therapeutics: Focused on Muscle Disease
Developing a novel therapeutic designed to protect muscle in Becker and Duchenne muscular dystrophy Watch HERE
REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy
In this webinar, Dr. Naz Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shared information on the active and enrolling AFFINITY DUCHENNE trial and how families […]
Craft Your Story
Crafting Your Story for Awareness, Connection, and Change Webinar. Watch HERE
REGENXBIO WEBINAR
AFFINITY DUCHENNE®: New Phase 1/2 Interim Functional Data. Watch HERE
Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study
Wave Life Science Exon Skipping in Duchenne Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s […]
Dyne Therapeutics: The clinical impact of the FORCE™ platform
Duchenne muscular dystrophy (DMD) – An update on the DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping. WATCH HERE
Dyne Therapeutics of DYNE-251 in Duchenne
Dyne Therapeutics shares with the community recent efficacy and safety data from the ongoing DELIVER trial of DYNE-251 in Duchenne. Watch HERE
ITF THERAPEUTICS| DUVYZAT Update
CureDuchenne Webinar | ITF THERAPEUTICS Patient Community Update: An overview of DUVYZAT Recorded on June 26, 2024Watch HERE